Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.
Auteurs : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE Jaar : 2022 Journal : Cells
Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.
Auteurs : Chouha N, Abou-Hamdan H, Yurugi H, Yoshii R, Ii H, Najem A, Ghanem GE, Nakata S, Rajalingam K, Peng Y, Wang D, Nebigil CG, Désaubry L Jaar : 2022 Journal : Eur J Med Chem
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.
Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A Jaar : 2022 Journal : Cells
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].
Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G Jaar : 2022 Journal : Eur J Cancer
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Auteurs : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F Jaar : 2021 Journal : Mol Cancer Res